The European EGPA Study Group was established in 2018 with the intention to create a network of scientists and clinicians from European EGPA referral centers, gathering clinical and scientific excellence and expertise to promote collaborative clinical and translational studies, to enhance knowledge about the disease, and to develop new recommendations about its diagnosis and treatment.

At present the European EGPA Study Group comprised more than 30 centers across Europe and actively collaborate with the other scientific groups and societies involved in the field of vasculitis, and with patients’ associations.


The European EGPA Study Group is based on the participation of International Referral Centers and leading experts involved in the diagnosis and treatment of patients with Eosinophilic Granulomatosis with Polyangiitis.

EGPA - Churg-Strauss syndrome

Eosinophilic Granulomatosis with Polyangitiis (also known as Churg-Strauss syndrome) is a rare systemic vasculitis characterized by inflammation of the blood vessels, primarily of small size, leading to blood flow restriction and to consequent damage of vital organs and tissues.
EGPA can be associated with pulmonary, ear-nose-throat, cutaneous, cardiac, intestinal, renal and neurological manifestations.
The symptoms of EGPA can range from mild to life-threatening, and may vary among individuals, however almost all patients have asthma and/or sinus polyps, and hypereosinophylia (i.e., an increased level of white blood cells called eosinophils).